Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axalimogene filolisbac in Anorectal Squamous Cell Carcinoma
NCT02399813Phase 2Completed
- Sponsor
- Advaxis, Inc.
- Start
- Jun 2016
- Primary completion
- Jan 2019
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axalimogene filolisbac in anal cancer and rectal cancer, sponsored by Advaxis, Inc. Primary endpoints: Objective Response Rate at 68 weeks and Progression Free Survival at 68 weeks. Started Jun 2016; status: completed.
02
Drugs
axalimogene filolisbac
03
Conditions
anal cancerrectal cancer
Beyond the preview
Go deeper on NCT02399813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02399813.